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ABSTRACT Proteus mirabilis is a common pathogen of the catheterized urinary tract
and often described as intrinsically resistant to the biocide chlorhexidine (CHD).
Here, we demonstrate that derepression of the smvA efﬂux system has occurred in
clinical isolates of P. mirabilis and reduces susceptibility to CHD and other cationic
biocides. Compared with other isolates examined, P. mirabilis RS47 exhibited a sig-
niﬁcantly higher CHD MIC (512g/ml) and signiﬁcantly greater expression of smvA.
Comparison of the RS47 smvA and cognate smvR repressor with sequences from other
isolates indicated that RS47 carries an inactivated smvR. Complementation of RS47
with a functional smvR from isolate RS50a (which exhibited the lowest smvA expres-
sion and lowest CHD MIC) reduced smvA expression by 59-fold and markedly low-
ered the MIC of CHD and other cationic biocides. Although complementation of
RS47 did not reduce MICs to concentrations observed in isolate RS50a, the signiﬁ-
cantly lower polymyxin B MIC of RS50a indicated that differences in lipopolysaccha-
ride (LPS) structure are also a factor in P. mirabilis CHD susceptibility. To determine if
exposure to CHD can select for mutations in smvR, clinical isolates with the lowest
CHD MICs were adapted to grow at increasing concentrations of CHD up to 512 g/
ml. Analysis of the smvR in adapted populations indicated that mutations predicted
to inactivate smvR occurred following CHD exposure in some isolates. Collectively,
our data show that smvA derepression contributes to reduced biocide susceptibility
in P. mirabilis, but differences in LPS structure between strains are also likely to be
an important factor.
KEYWORDS Proteus mirabilis, biocides, bioﬁlms, catheter, chlorhexidine, efﬂux,
lipopolysaccharide, urinary tract infection
Biocides play an important role in infection control and are often used to removemicrobes from equipment, surfaces, and skin prior to medical procedures (1–3). The
rising incidence of multidrug resistance in nosocomial pathogens has further magniﬁed
the clinical value of biocides, and there is increasing reliance on these antimicrobials to
reduce antibiotic usage through more effective infection control strategies (1, 4–6).
However, despite their clinical signiﬁcance, biocides are subject to far fewer regulations
on their use than therapeutic agents, such as antibiotics (2). In many applications, there
is also little or no direct evidence that biocide use is beneﬁcial, and they are often used
without a clear indication (3, 7, 8).
Commensurately, there is mounting concern that the inappropriate or overuse of
biocides will lead to the emergence of biocide-resistant strains and could select for
cross-resistance to antibiotics (1–5, 7, 9, 10). This would not only undermine the efﬁcacy
of these valuable agents but also exacerbate the problem of antimicrobial resistance
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and reduce our ability to control the spread of resistant organisms. This is exempliﬁed
by our previous work, which demonstrated that clinical isolates of Klebsiella pneu-
moniae can adapt to grow at increasing concentrations of chlorhexidine (i.e., become
more resistant), and adaptation is associated with the acquisition of colistin resis-
tance (4).
Chlorhexidine (CHD) is used extensively in health care settings both as a disinfectant
and antiseptic. It is incorporated into a range of products, such as wipes, hand washes,
wound dressings, irrigation solutions, and lubricating gels, and routinely applied to
prevent infection (1, 2, 5, 7, 11–15). Examples of applications include the prevention of
ventilator-associated pneumonia, the decontamination of skin at puncture or incision
sites, control of wound infections, hard surface disinfection, decolonization of patients
carrying opportunistic pathogens, such as methicillin-resistant Staphylococcus aureus
(MRSA), and prevention of infections related to central venous catheterization (5, 7, 8,
13–16). CHD is also commonly used in a range of domestic health care products, such
as mouthwashes and antiseptics (2, 7, 11, 14, 15), and as a teat wash in the veterinary
ﬁeld (17, 18). The diverse formulations and uses of CHD mean that in-use concentra-
tions can vary from 0.015% to 0.02% for catheter maintenance solutions and wound
irrigation products to 4% for surgical scrubs and other skin antiseptic products (4, 19).
Therefore, pathogens present in the clinical environment are likely to encounter CHD
at a wide range of concentrations, including sublethal levels that can potentially select
for CHD tolerant strains.
Increased CHD resistance in adapted K. pneumoniae strains generated in our previ-
ous work was associated with mutations in a putative Tet repressor gene (smvR) that
result in increased expression of the cognate smvA efﬂux system (4). The SmvA efﬂux
pump is a member of the major facilitator superfamiliy (MFS) of transporters and was
ﬁrst described in Salmonella enterica serovar Typhimurium, where it was associated
with efﬂux of quaternary ammonium compounds (QACs) and methyl-viologen resis-
tance (20, 21). SmvA has now also been implicated in cationic biocide resistance in
other members of the Enterobacteriaceae family and is potentially an important biocide
resistance determinant in several clinically relevant Gram-negative species (2, 6). How-
ever, to date, we have only observed mutations in smvR that lead to reduced CHD
susceptibility in K. pneumoniae and other species in laboratory experiments, and the
clinical relevance of this biocide resistance mechanism remains unclear.
Proteus mirabilis is a prominent pathogen of the catheterized urinary tract and is
associated with serious clinical complications (9, 22–24). This stems from the ability of
P. mirabilis to form extensive crystalline bioﬁlms on catheter surfaces, which result in
obstruction of urine ﬂow. In turn, this leads to the reﬂux of infected urine to the kidneys
and precipitates the onset of pyelonephritis and septicemia (22–24). Resistance to CHD
has been reported in P. mirabilis since the late 1960s, with initial studies conducted on
isolates surviving the application of antiseptic preparations used in attempts to prevent
catheter-associated urinary tract infections (25–27). The selection of strains resistant to
high concentrations of CHD and a range of antibiotics, through repeated CHD expo-
sure, has also been documented in clinical settings (9, 25–31). Nonetheless, many
catheter maintenance solutions and lubricating gels still contain CHD, and it is likely
that P. mirabilis is still often exposed to various concentrations of CHD as a nosocomial
pathogen.
Despite its longstanding reputation as a CHD-resistant organism, the underlying
mechanisms of CHD resistance in P. mirabilis are not well studied, and resistance is
generally attributed to aspects of cell permeability. However, this species carries a
homologue of the smvAR gene locus associated with adaptation to CHD in K. pneu-
moniae and other Enterobacteriaceae (4, 6). Therefore, we hypothesized that a greater
understanding of CHD resistance in P. mirabilis could offer further insight into the
development of clinically relevant mechanisms of CHD resistance, including the po-
tential for smvR mutations to arise naturally in the clinical environment. Here, we
identify and characterize a clinical isolate of P. mirabilis with defects in smvA regulation
and high-level CHD resistance. We utilize this as a clinically relevant model organism to
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determine the role smvA overexpression plays in modulating susceptibility to a range
of antimicrobials, as well as the impact on crystalline bioﬁlm formation, which consti-
tutes a key aspect of P. mirabilis pathogenicity.
RESULTS
Susceptibility of P. mirabilis clinical isolates to chlorhexidine. To identify P.
mirabilis clinical isolates with high-level CHD resistance, we determined the MIC of CHD
for a panel of 10 isolates from urinary tract infections (Table 1). A wide variation in CHD
MICs was observed for these isolates, with isolate RS50a exhibiting the lowest MIC.
Conversely, isolate RS47 displayed considerably greater tolerance than all other isolates
and was able to grow at the maximum CHD concentration that could be evaluated
(Table 1).
Comparison of smvAR loci. To test the hypothesis that changes in smvA expression
can modulate P. mirabilis CHD susceptibility, we ﬁrst compared the smvAR genes from
all 10 isolates (Fig. 1). Alignments of translated amino acid sequences from the SmvA
efﬂux pump in these isolates showed a range of single amino acid substitutions primarily
toward the C-terminal end (Fig. 1a). However, differences in SmvA sequences were not
correlated with CHD susceptibility (Fig. 1a; Table 1). Conversely, alignments of the SmvR
repressor sequence (which controls expression of smvA), revealed notable differences
between the high-level CHD-resistant RS47 and other isolates (Fig. 1b). All differences
between SmvR sequences were localized to a 30-amino acid (aa) region in the C
terminus of the translated amino acid sequence and, in most cases, were related to
single amino acid substitutions (e.g., RS50a, B4, and B2) (Fig. 1b). In contrast, RS47
exhibited a 22-aa truncation in the SmvR C terminus and substitutions in the 9
preceding amino acids (Fig. 1b). Further analysis of the RS47 smvR nucleotide sequence
indicated a point mutation has resulted in the formation of a premature stop codon,
which leads to truncation of the predicted amino acid translation.
Impact of smvRmutations on smvA expression. To determine if the differences in
SmvR amino acid sequences observed in these isolates corresponded to differences in
expression of the cognate smvA efﬂux system, we measured expression of smvA in a
subset of isolates using reverse transcriptase quantitative PCR (RT-qPCR) (Fig. 2).
Isolates chosen represented the observed range of SmvR sequence types in amino acid
alignments (Fig. 1). An overall correlation between smvA expression and susceptibility
to CHD was observed (R2, 0.9; P 0.015). Isolate RS47, carrying a truncated SmvR and
exhibiting the lowest susceptibility to CHD, displayed the highest level of smvA
expression compared with the other 4 isolates tested (Fig. 2). Conversely, isolate RS50a,
exhibiting the greatest susceptibility to CHD, displayed the lowest level of smvA
expression. For isolates with intermediate CHD susceptibilities (B2, B4, and RS28), a
greater but more variable level of smvA expression was observed, although these were
not statistically signiﬁcant differences compared with RS50a expression (Fig. 2).
Expression of smvA following exposure to chlorhexidine. To determine if expo-
sure to low levels of CHD inﬂuences the expression of smvA, we measured expression
in RS50a (most CHD susceptible) and RS47 (least CHD susceptible) following exposure
to sub-MIC levels of CHD (0.25 RS50a MIC). After CHD exposure, expression of smvA
TABLE 1 Susceptibility of P. mirabilis clinical isolates to chlorhexidine digluconate
Isolate MIC (g/ml)
B2 32–128
B4 32–64
RS1 16
RS6 32–64
RS17 16–64
RS18 32–64
RS28 128–256
RS40 32
RS47 512
RS50a 8–16
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was signiﬁcantly increased in both isolates compared with expression in unexposed
subsamples of the same cultures (Fig. 3). However, RS50a displayed a notably larger
relative increase in smvA expression following CHD exposure than RS47 (Fig. 3).
Role of SmvA in modulating susceptibility to CHD and other antimicrobials. To
conﬁrm that overexpression of smvA was related to the CHD-resistant phenotype
FIG 1 Comparison of SmvAR sequences. The smvAR locus was identiﬁed in draft genome sequences from P. mirabilis isolates analyzed for CHD
susceptibility. Translated SmvR and SmvA amino acid sequences from all isolates were compared further by ClustalW alignment. (A) Shows alignments
of SmvA sequences. B) Shows alignments of SmvR sequences. Amino acid residues that varied from the majority consensus between isolates are
highlighted by symbols. The 22-amino acid truncation at the C terminus of RS47 SmvR is highlighted by the black dashed box.
FIG 2 Expression of smvA in Proteus mirabilis strains. Quantitative real-time PCR was used to measure the
expression of smvA in selected P. mirabilis isolates. Isolates chosen represent SmvR sequences with the
range of amino acid variations observed (Fig. 2). A calibration curve of plasmid DNA containing an smvA
fragment was used to determine absolute quantiﬁcation. Expression of smvA is shown as copies per ng
of cDNA template used. Data represent the mean of three biological replicates, with two technical
replicates performed in each. Error bars show standard error of the mean. One-away ANOVA and
Bonferroni’s post hoc test were performed comparing RS50a to other P. mirabilis strains. ****, P  0.0001
versus RS50a. The average fold difference in smvA expression of each isolate relative to RS50a is provided
by numbers on bars.
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observed in RS47, a functional copy of smvR from isolate RS50a was introduced to RS47
on a plasmid vector. Measurement of smvA gene expression in the complemented RS47
derivative (designated RS47::RS50AsmvR) conﬁrmed that activity of the RS50a smvR in
the RS47 background signiﬁcantly reduced smvA expression compared with the wild
type and RS47 carrying an empty vector (Fig. 4). MIC measurements conﬁrmed that
reduced smvA expression corresponded to an increase in CHD susceptibility (Table 2).
Role of SmvA in modulating susceptibility to other antimicrobials. To test the
effect of altered smvA expression on susceptibility to other antimicrobial agents in P.
mirabilis, we determined MICs of a range of antibiotics and biocides against the most
CHD-susceptible isolate RS50a, the high-level CHD-resistant isolate RS47, and the
complemented RS47::RS50AsmvR (carrying a functional smvR from RS50a). For the
antibiotics tested, no notable differences were seen between the strains, with the ex-
ception of polymyxin B (PMB), to which P. mirabilis is also considered to be intrinsically
resistant. In this case, RS50a exhibited a notably reduced PMB MIC compared with RS47
FIG 3 SmvA expression in Proteus mirabilis following chlorhexidine digluconate exposure. Quantitative
real-time PCR was used to measure the expression of smvA in P. mirabilis following exposure to a sub-MIC
of CHD. Exposure was to 4 g/ml (0.25 RS50a MIC) for 15 min, and copies of smvA per nanogram cDNA
template calculated. Data are expressed as fold change in svmA expression in CHD-exposed cells relative
to unexposed cells. Data represent the mean of three biological replicates (with duplicated technical
replicates for each), and error bars show standard error of the mean. Symbols indicate statistical
signiﬁcance of changes in smvA expression for each isolate compared with cells without CHD exposure.
Statistical comparisons between CHD-exposed cells and unexposed cells of each isolate performed using
a t test. *, P  0.05; **, P  0.01.
FIG 4 Impact of smvR complementation of RS47 smvA expression. Quantitative real-time PCR was used
to measure the expression of smvA in the wild-type RS47 isolate and the derivatives RS47::RS50AsmvR
and RS47::pGEM-Tempty, harboring constructs with a functional copy of smvR or empty vector, respec-
tively. Expression of smvA is shown as copies per nanogram of cDNA template from each strain. Data
represent the mean of three biological replicates (with duplicated technical replicates performed in
each), and error bars show standard error of the mean. One-way ANOVA and Bonferroni’s post hoc test
were performed to identify signiﬁcant differences in smvA expression between the wild type and
transformants. *, P  0.01 versus RS47.
P. mirabilis Biocide Susceptibility and smvA Efﬂux Antimicrobial Agents and Chemotherapy
December 2019 Volume 63 Issue 12 e01535-19 aac.asm.org 5
 o
n
 N
ovem
ber 22, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
and its derivatives (Table 2). All other clinical isolates displayed PMB MICs comparable
to RS47.
Across all biocides tested, RS47 had considerably higher MICs than RS50a, ranging
from 2- to 128-fold higher (Table 2). The presence of a functional copy of smvR
in RS47::RS50AsmvR resulted in increased susceptibility to most biocides, with MICs
between 4-fold and 64-fold lower than the RS47 wild type (WT) (Table 2). This was most
notable for the quaternary ammonium compounds cetrimide, cetylpyridinium chloride,
hexadecylpyridinium chloride monohydrate, and cetrimonium bromide (Table 2). How-
ever, provision of a functional smvR did not reduce RS47::RS50AsmvR MICs to values
comparable to those of the RS50a donor strain in several cases. This was most apparent
for CHD, where the RS47::RS50AsmvR MIC remained 16-fold greater than that of RS50a
(Table 2). MIC results for RS47 harboring the vector alone (RS47::pGEM-Tempty) were
comparable to those of RS47 WT, with minor differences (2-fold) for some biocides
not considered signiﬁcant in these assays.
Analysis of smvR mutations arising in chlorhexidine-adapted P. mirabilis pop-
ulations. In order to understand if CHD exposure selects for mutations in smvR, P.
mirabilis isolates with the greatest susceptibility to CHD (RS50a, RS1, and B4) and lowest
known smvA expression (RS50a and B4), were adapted to grow at increasing concen-
trations of CHD. Analysis of smvR in populations adapted to grow at 512-g/ml CHD
demonstrated a range of mutations in smvR had occurred in response to CHD exposure
(Table 3). For CHD-adapted populations derived from isolates RS1 and B4, a variety of
single nucleotide polymorphisms (SNPs) were detected, which were predicted to lead
to either amino acid substitutions or the development of premature stop codons (Table
3). In the B4 CHD-adapted population, a duplication of 8 bp at position 282 occurred at
a frequency of 7.4% and caused a frameshift mutation that ultimately leads to a
premature stop codon at codon 108 (Table 3). Also identiﬁed in the adapted B4
population was a 14-bp deletion at position 467 which occurred at a lower frequency
(1.3%) but also lead to a frameshift mutation, resulting in a premature stop codon at
codon 157 (Table 3). In RS1 CHD-adapted populations, a SNP at position 10 occurred
with a frequency of 13.7% and is predicted to lead to a premature stop codon at codon
4 (Table 3). In the RS50a population, a single SNP at position 70 was identiﬁed with
100% frequency, resulting in a glycine-to-arginine substitution at position 14 (Table 3).
TABLE 2MIC values of various antibiotics and biocides for wild-type and complemented
isolates
Antimicrobiala
MIC (g/ml) by isolateb
RS50a RS47 RS47::pGEM-Tempty RS47::RS50AsmvR
Biocides
CHD 8–16 512 512 128–256
OCT 1–2 64–128 32–64 4–32
BZK 16 128 64–128 16–32
CET 8 256–512 256–512 32–64
CPC 4 256–512 128–256 16
CTAB 8 256–512 256–512 8
HDPCM 4–8 256 64–128 16–32
Antibiotics
PMB 128 to 256 2,048 2,048 2,048
NAL 4 to 8 4 2 to 4 4
FOF 128 256 to 512 256 256 to 512
GEN 16 8 to 16 4 to 16 4 to 16
CHL 32 16 to 32 8 to 16 8 to 16
TMP 4 to 8 4 to 8 1 to 4 2 to 4
CIP 0.016 to 0.06 0.06 to 0.25 0.03 to 0.125 0.03 to 0.06
AMX 4 2 * *
aCHD, chlorhexidine digluconate; OCT, octenidine; BZK, benzalkonium chloride; CET, cetrimide; CPC,
cetylpyridinium chloride; CTAB, cetrimonium bromide; HDPCM, hexadecylpyridinium chloride monohydrate;
NAL, nalidixic acid; FOF, fosfomycin; GEN, gentamicin; CHL, chloramphenicol; TMP, trimethoprim; CIP,
ciproﬂoxacin; AMX; amoxicillin.
b*, Isolates that required ampicillin selection were not tested against amoxicillin.
Pelling et al. Antimicrobial Agents and Chemotherapy
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Role of smvA in crystalline bioﬁlm formation and catheter blockage. Efﬂux
systems have recently been highlighted as important to the development of crystalline
bioﬁlms in P. mirabilis, which are a key aspect of P. mirabilis pathogenesis in the
catheterized urinary tract (32, 33). This raises the potential for alterations in SmvA
activity to also inﬂuence the formation of crystalline bioﬁlms. To test this, we evaluated
the ability of RS47 and its smvR-complemented derivative to form crystalline bioﬁlms
and block urinary catheters using an in vitro infection model (Fig. 5). However, no
signiﬁcant differences in ability to block catheters was observed between RS47::
RS50AsmvR and RS47::pGEM-Tempty (Fig. 5a). Both strains also showed comparable
TABLE 3 Analysis of smvR mutations arising in chlorhexidine-adapted populations
Parent NTa position Mutationb Frequencyc (%) Amino acid changed
B4 7 CT 1.5 R3C
15 AC 5.4 R5S
85 AG 10.0 T29A
101 CT 1.4 A34V
282 (ATGATCAC)12 7.4 D95M, K96I, L97T, S98I, F99S,
A100S, K101L, G102L,
A103P, S104K, L105E,
M106P, A108*
307 GT 2.2 A103S
323 CT 3.3 A108V
460 CT 1.4 R154W
467 Δ14 bp 1.3 F156Y, G157*
530 TG 11.1 L177R
RS1 10 CT 13.7 Q4*
101 CT 2.0 A34V
292 TC 15.3 S98P
313 TG 33.4 L105V
RS50a 70 GA 100 G14R
aNT, nucleotide position in smvR.
bMutations, NT substitution (e.g., C T); duplication (e.g., [ATGATCAC] 1 2); deletion (e.g., Δ14 bp).
cFrequency, predicted frequency of sequences containing the mutation.
dAmino acid change, reference aa; aa position; new aa. Substitutions highlighted in bold indicate those
where mutations lead to formation of a stop codon (*), predicted to truncate the translated protein at the
indicated position.
FIG 5 Impact of smvA overexpression on P. mirabilis crystalline bioﬁlm formation. In vitro infection models simulating catheter-associated urinary tract infection
were used to determine if smvA derepression inﬂuences crystalline bioﬁlm formaiton. Models were used to simulate established infections with starting cell
numbers of 108 CFU/ml in residual “bladder” urine and ability to form crystalline bioﬁlms assessed by time taken for catheters to become blocked. (A) Time
taken for catheters to block. (B) pH of residual bladder urine at time of blockage. (C) Viable cells in residual bladder urine at catheter blockage. Data represent
the mean from a minimum of four replicate experiments, and error bars show standard error of the mean. No statistically signiﬁcant differences in time to
blockage or pH and CFU/ml at blockage between isolates tested were identiﬁed (t test).
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ability to elevate the pH of artiﬁcial urine and persist in these in models (Fig. 5b and c).
Collectively, these results indicate that changes in smvA expression related to reduced
biocide susceptibility do not inﬂuence the ability to form crystalline bioﬁlms on
catheters by P. mirabilis.
DISCUSSION
Here, we demonstrate that mutations leading to the overexpression of the smvA
efﬂux system are present in clinical isolates of P. mirabilis and reduce the susceptibility
of this organism to a range of cationic biocides. Characterization of the clinical P.
mirabilis isolate RS47, which exhibits high-level CHD tolerance, provided clear evidence
that derepression of smvA, through inactivation of the cognate smvR repressor, is
associated with increased tolerance to CHD and other cationic biocides. Subsequent
experiments also indicated that smvA expression was increased upon CHD exposure,
and smvR mutations arose in P. mirabilis populations after they were adapted to grow
at increasing concentrations of CHD (up to 512 g/ml). Conversely, smvA upregulation
did not affect P. mirabilis susceptibility to the antibiotics tested in this study or
modulate the ability to form crystalline bioﬁlms on urethral catheters.
Defects in the smvR repressor analogous to those observed in RS47 were associated
with the acquisition of CHD resistance in our previous studies of K. pneumoniae,
following adaptation to increasing concentrations of CHD in the laboratory (4, 6). But
P. mirabilis RS47 provides the ﬁrst evidence that such mutations can arise in pathogens
in the clinical environment. Other MFS transporters have also previously been linked
with resistance to multiple biocides in both Gram-positive and Gram-negative species
(2, 34–37). For example, MdfA of Escherichia coli and the QacA system from Staphylo-
coccus aureus confer resistance to a wide range of cationic compounds from distinct
chemical classes, including biocides (35–37). However, the results of this study further
support our recent work highlighting SmvA as an important efﬂux pump for cationic
biocides in multiple Gram-negative species and the potential for CHD exposure to
select for mutations that promote cross-resistance to multiple biocides (6). Although
not directly demonstrated in this study, we assume that overexpression of smvA leads
to an increase in the quantity of SmvA efﬂux pumps present in the cytoplasmic
membrane, which is responsible for the observed changes in phenotype. However, it
should be noted that increased mRNA production does not always correlate with
increased protein production, and other posttranscriptional or posttranslational mech-
anisms could inﬂuence the ﬁnal amount of SmvA produced.
Nevertheless, while our data clearly indicate a contribution of the smvA system to
reduced biocide susceptibility in P. mirabilis, it is more difﬁcult to deﬁne where such
changes in susceptibility would equate to clinically relevant biocide “resistance.” This
stems from the use of biocides at a wide range of concentrations in numerous distinct
products, the variety of applications in which biocides are used, and the inclusion of
other compounds with potential antimicrobial activity in many products. Moreover,
although actual in-use concentrations of biocides are often many times greater than
MICs for bacterial pathogens, biocides are often required to work in challenging
environments and parameters such as temperature, organic load, and exposure time all
inﬂuence overall efﬁcacy in terms of microbial killing. As such, deﬁnitions of resistance
or clinical breakpoints are not well established for biocides, and interpretation of
biocide resistance is often more complex than the simple relationship between the MIC
of a bacterial strain and the in-use concentration of a biocide.
However, as P. mirabilis is a particularly problematic pathogen of the catheterized
urinary tract associated with serious clinical complications, its potential to overcome
the application of CHD-containing products used in catheter care is especially relevant
(9, 26–31, 38). A notable example is bladder washout solutions containing 0.02% wt/vol
chlorhexidine (200 g/ml). At the time of writing, these products are available on the
UK National Health Service (NHS) supply chain for urinary catheter maintenance and
contain no other antimicrobial agents or ingredients expected to enhance biocide
activity. Since the CHD MIC recorded for RS47 is considerably greater than the CHD
Pelling et al. Antimicrobial Agents and Chemotherapy
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concentration in this product, it can be reasonably proposed that smvA derepression
could confer clinically relevant CHD resistance in at least some situations relating to
bladder antisepsis. In addition, the propensity for P. mirabilis to form bioﬁlms on
catheter surfaces will contribute to further reductions in biocide susceptibility, and it is
likely that cells embedded within bioﬁlms will not be exposed to the full working
concentration of antimicrobial agents contained within antiseptic products (9, 19, 32,
33, 39).
Notably, biocide susceptabilities modulated by smvA expression also included oc-
tenidine and a range of quaternary ammonium compounds (QACs), an observation that
differs from previously published data from other Enterobacteriaceae (4, 6). Octenidine
is increasingly used as a substitute for CHD and has been claimed to not promote
resistance when used as recommeneded (40, 41). The overall contribution of smvA
overexpression to octenidine susceptibility appeared to be much more pronouned
than for CHD, with restoration of smvR activity reducing the octenidine MIC by 4- to
16-fold in RS47. However, the lowest concentration of octenidine currently contained
in a commercially available product is 0.05% wt/vol for the Octenilin wound irrigation
solution. As such, the RS47 MIC for octenidine remains well below in-use concentrations
(provided the product is used as intended by the manufacturers), and it remains unclear
if the reduced susceptibility we observed is relevant to clinical practice.
Nevertheless, our ﬁndings are in keeping with recent studies showing that P.
aeruginosa and K. pneumoniae can adapt to octenidine challenge and develop stable
reductions in susceptibility to in-use concentrations (6, 42). Furthermore, isolates of
Stapylococcus aureus with increased octenidine MICs and minimal bactericial concen-
trations (MBCs) were found to rapidly emerge in clinical environments when octenidine
use was introduced for decolonizing patients of MRSA (5). Our ﬁndings also ﬁt well with
data indicating that changes in smvA activity maybe a common mechanism of reduced
susceptibility to both CHD and octenidine in a range of Gram-negative species (6).
Overall, the phenotype of P. mirabilis RS47 suggests that reduced octenidine suscep-
tibility in this species is already present in the clinical environment through smvA
upregulation, and the implications for infection control warrant further monitoring.
Although our data clearly point to a role for smvA derepression in increasing P.
mirabilis biocide tolerance, the examination of wider biocide and antibiotic suscepti-
bilites in isolates we characterized also provides evidence that LPS structure is an
important factor in the overall biocide susceptibility proﬁle of P. mirabilis. In this regard,
it is well established that properties of the Gram-negative bacterial cell envelope play
a key role in the susceptibility of particular strains and species to biocides and other
antimicrobials by inhibiting penetration of these agents into the cell and limiting their
interaction with cellular targets (primarily the cytoplasmic membrane for cationic
biocides such as CHD) (11, 12, 27, 43–45). Of particular interest in this context was the
notably lower polymyxin B (PMB) MIC observed in RS50a than that in other isolates,
which was not associated with smvA expression. PMB resistance in P. mirabilis stems
from incorporation of the positively charged 4-amino-4-deoxy-L-arabinose (L-Ara4N)
into the lipid A component of LPS (46–49). This modiﬁcation reduces the overall
negative charge of the outer membrane, leading to repulsion of cationic peptides, such
as PMB, and a reduction in the susceptibility of P. mirabilis to these antimicrobials
(45–49). Therefore, the lower PMB MIC observed in isolate RS50a is likely to be
indicative of differences in LPS structure compared with other isolates, which increases
the overall net negative surface charge of RS50a.
Because CHD is also a cationic compound, alterations in LPS net charge are also
likely to modulate LPS permeability to CHD (1, 12, 44). If so, this feature of RS50a could
also explain why restoration of smvR activity in RS47 did not reduce the CHD MIC to
concentrations comparable to the RS50a smvR donor. Conversely, smvR complemen-
tation did reduce the RS47 CHD MIC to concentrations comparable to those found in
other clinical isolates where smvA expression was analyzed (B2, B4, and RS28) and
which also exhibited PMB MICs identical to RS47. Moreover, individual RS50a CHD-
resistant mutants isolated from populations adapted to grow at 512 g/ml CHD all
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exhibited PMB MICs comparable to RS47 and other isolates in this regard. It is also
notable that previous CHD adaption experiments with K. pneumoniae resulted in
activation of pathways controlling the incorporation of L-Ara4N into LPS and increased
colistin resistance (4, 50).
Collectively, these data indicate that the overall susceptibility proﬁle of P. mirabilis
to cationic biocides is likely to result from the interplay between both LPS permeability
and active efﬂux. While LPS structure is an important factor governing the initial entry
of biocides, such as CHD, into the cell, mutations in smvR and overexpression of the
smvA efﬂux system can confer additional protection and further reduce susceptibility.
This hypothesis is also congruent with recent studies seeking to distinguish the speciﬁc
relative contributions of active efﬂux and outer membrane diffusion to overall antimi-
crobial susceptibility in Gram-negative bacteria, which illustrate how these key barriers
cooperate to confer protection against a wide range of structurally unrelated antibiotics
(45). Although further study will be required to fully understand the relative contribu-
tions of LPS structure and active efﬂux to biocide susceptibility in Gram-negative
species, the development of new biocides will likely beneﬁt from more detailed and
systematic studies of how existing compounds interact with both aspects of bacterial
cells.
The contribution of SmvA to cationic biocide susceptibility in P. mirabilis and other
species also raises questions regarding the exact mechanism by which efﬂux confers
protection against these agents. MFS efﬂux systems, such as SmvA, are usually consid-
ered to be single component pumps localized to the inner membrane, where they work
to remove toxic substances from inside the cell, or from the cytoplasmic membrane
itself, into the periplasm (2, 51–53). However, the main lethal effect of cationic biocides,
such as CHD and quaternary ammonium compounds (QACs), is considered to be
disruption of cytoplasmic membrane structure and function (1, 2, 11). The action of
biocides could also disrupt the function of MFS transporters through perturbation of
the proton motive force on which they rely (2). Therefore, efﬂux systems that export
substrates into the periplasmic space would not logically be expected to confer
resistance to CHD unless there is also involvement with outer membrane transporters,
such as OmpD and OmpW, which are linked to SmvA-mediated resistance to paraquat
in S. Typhimurium (1, 2, 21, 54). One possibility is that SmvA does not work as a single
component system but is instead part of a cell-envelope spanning complex with these
proteins that is able to remove toxic compounds from the periplasm as well as the
cytoplasm. Studies of MFS systems in other species have demonstrated that some MFS
transporters do form tripartite systems with periplasmic linker proteins and outer
membrane porins, analogous to the better characterized resistance-nodulation-division
(RND) pumps, to transport substances out of the cell (51, 55, 56).
Consideration should also be given to the possibility that SmvA does not primarily
modulate biocide susceptibility by exporting antimicrobials directly but instead
through the export of substrates that contribute to wider physiological processes and
stress responses (2). For example, single component pumps from the MFS, small
multidrug-resistant (SMR), and multidrug and toxic compound extrusion (MATE) fam-
ilies are known to have roles in osmoregulation and expulsion of osmoprotectants from
cells, which could conceivably contribute to offsetting membrane damage and reduced
functionality caused by biocides, such as CHD (2). Further detailed research will be
required to clearly elucidate the mechanism through which MFS transporters, such as
SmvA, facilitate biocide resistance, and a better understanding of these systems is likely
to improve knowledge of numerous physiological processes in bacterial cells.
In conclusion, this study provides further evidence that the SmvA efﬂux system is an
important factor modulating susceptibility to cationic biocides among Gram-negative
bacteria. Moreover, we provide the ﬁrst evidence that mutations leading to overex-
pression of smvA and broad-spectrum increases in cationic biocide tolerance have
already occurred in the clinical environment and elevate MICs to concentrations that
are likely to undermine the clinical use of some antiseptic formulations. In this context,
our work adds to existing evidence that CHD-containing catheter care products are of
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questionable clinical beneﬁt and there is a well-established link between CHD usage
and selection of multidrug-resistant strains of P. mirabilis (9, 26–31, 38). The continued
availability of urinary catheter products containing CHD in the NHS supply chain is,
therefore, cause for considerable concern. More broadly, the clinical importance of
biocides in infection control alone should provide sufﬁcient grounds for greater sur-
veillance of biocide resistance and the impact this may have on clinical efﬁcacy of
antiseptics, other antimicrobials, and infection control practices. The possibility that
SmvA may also work in synergy with changes to the outer membrane, which is linked
with resistance to antibiotics of last resort, such as colistin, adds further weight to this
argument. If so, then efforts to control the spread of antibiotic resistance could also
beneﬁt from a greater understanding of the mechanisms underlying biocide resistance.
MATERIALS AND METHODS
General culture and media. Clinical isolates of Proteus mirabilis used in this study were obtained
from The Royal Sussex County Hospital and Bristol Southmead Hospital. Table 4 provide details of isolates
and derivatives used in this study. Unless stated otherwise, bacteria were cultured in lysogeny broth (LB)
(10 g/liter tryptone, 5 g/liter yeast extract, and 10 g/liter sodium chloride) or tryptic soya broth (TSB) (17
g/liter pancreatic digest of casein, 3 g/liter enzymatic digest of soya bean, 5 g/liter sodium chloride, 2.5
g/liter dipotassium hydrogen phosphate, and 2.5 g/liter glucose) at 37°C with aeration. For growth on
solid media for isolation of single colonies, LB agar without salt (1.5% wt/vol agar) or MacConkey number
3 agar was used.
Determination of MIC. The MIC of antibiotics and biocides, including CHD (Sigma-Aldrich) was
determined using a broth microdilution method in 96-well polypropylene plates (Greiner Bio-One) for
cationic compounds (57) and 96-well polystyrene plates (Corning) for antibiotics. Wells containing TSB
with doubling dilutions of antimicrobial were inoculated with 1 105 CFU/ml log-phase P. mirabilis
cells and incubated statically for 20 h at 37°C. Wells containing isolates which required ampicillin
selection were supplemented with 100-g/ml ampicillin. Growth was determined by measuring optical
density at 600 nm (OD600). The MIC was deﬁned as the lowest concentration that inhibited measurable
growth.
TABLE 4 List of isolates and derivatives used in this study
Strain by bacterial species Comment(s) Source
P. mirabilis
B2 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
B4 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS1 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS6 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS17 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS18 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS28 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS40 Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS47 Displays high level chlorhexidine resistance (512 g/ml) and de-repression
of the smvA efﬂux system. Clinical isolate from urinary tract infection.
Royal Sussex County Hospital or
Bristol Southmead Hospital
RS50a Clinical isolate from urinary tract infection. Royal Sussex County Hospital or
Bristol Southmead Hospital
RS47:RS50AsmvR Derivative of isolate RS47 harboring functional copy of smvR repressor of
smvA cloned from RS50a. The relevant RS50a fragment encoding smvR
and upstream region encoding native promoter is cloned into the pGEM-
T vector, which confers resistance to ampicillin.
This study
RS47:pGEM-Tempty Derivative of isolate RS47 harboring empty pGEM-T vector Used as control
for studies of effect of smvR complementation in RS47:RS50AsmvR.
This study
E. coli
JM109 Standard cloning strain. Used as intermediate host for plasmid constructs
harboring RS50A smvR (used in complementation of RS47) or fragments
of B4 smvA (used as qPCR standards).
Promega, UK
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Genome sequencing and smvAR analysis. To evaluate potential differences in the smvAR genes
across P. mirabilis isolates, whole-genome sequences were obtained using the PHE Galaxy platform as
previously described (6, 58). smvAR loci in P. mirabilis were identiﬁed based on homology to the K.
pneumoniae smvA sequence (GenBank accession number SSJ85692). Translated amino acid sequences
from individual smvA and smvR open reading frames (ORFs) in each isolate were recovered and aligned
pairwise using Clustal W implemented in Geneious 9.8.1.
Measurement of smvA expression. Expression of smvA was measured by RT-qPCR using primers
SMVA-F and SMVA-R (Table 5). RNA was extracted from mid-log-phase bacterial cells using the total RNA
RNeasy PowerMicrobiome kit (Qiagen). Cells were harvested by centrifugation (13,000 g), resuspended
in 100 l PBS and processed immediately. Extractions were conducted according the manufacturer’s
instructions, including the optional addition of 100 l phenol-chloroform-isoamyl alcohol at 25:24:1
(vol/vol/vol) saturated with 100 mM Tris (pH 8.0; Sigma-Aldrich) to the PowerBead tube prior to the
addition of the sample. The recovered RNA was treated using the DNase Max kit (Qiagen) according
to the manufacturer’s instructions. DNase-treated RNA was used as the template (500 ng per
reaction) to generate cDNA using a QuantiTect reverse transcription (RT) kit (Qiagen). qPCR was
carried out in 25-l reactions using a Rotor-Gene Q cycler with a Rotor-Gene SYBR green PCR kit
(Qiagen). Each 25-l reaction contained 12.5 l 2 Rotor-Gene SYBR green PCR master mix, 100-ng
cDNA template, and 10 pmol of each forward and reverse primer made to volume with nuclease-free
water. For each of three biological replicates measured, duplicate technical replicates were con-
ducted. Negative controls consisted of reaction mixtures containing no template cDNA, and reaction
mixtures containing DNase-treated RNA to conﬁrm removal of contaminating chromosomal DNA. A
calibration curve of DNA standards (pGEM-T easy carrying a fragment of smvA from P. mirabilis B4)
(see also Table 4 and 5) was included in each replicate experiment to permit quantiﬁcation of smvA
transcripts.
Measurement of smvA expression following exposure to chlorhexidine. Overnight cultures were
diluted to OD600 of 0.1 in 10 ml LB and incubated for 1.5 h with shaking at 37°C to prepare mid-log-phase
cells. Two 1-ml aliquots of each culture were pelleted by centrifugation (13,000  g) and resuspended
in either LB or LB supplemented with 4 g/ml CHD. The resulting cell suspensions were incubated at
room temperature for 15 min, before being harvested by centrifugation (13,000  g) and resuspended
in 100 l PBS and 500 l RNAlater (Invitrogen). Samples were stored in RNAlater at room temperature
overnight before processing. RNA extractions and RT-qPCR were conducted as described for measure-
ment of smvA expression above, also using SMVA-F and SMVA-R primers (Table 5).
Complementation of RS47 with a functional smvR. The smvR from wild-type P. mirabilis isolate
RS50a was ampliﬁed by PCR using primers SMVR-BAMHI-F and SMVR-BAMHI-R (Table 5) and Taq PCR
core kit reagents (Qiagen). Resulting PCR products were puriﬁed using a QIAquick gel extraction kit
(Qiagen) and ligated into the pGEM-T easy vector (Promega), according to the manufacturer’s instruc-
tions. Resulting constructs were introduced into chemically competent E. coli JM109 cells (Promega)
according to the pGEM-T easy vector system transformation protocol, and transformants were se-
lected on LB agar supplemented with 100 g/ml ampicillin, 80 g/ml 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-Gal), and 0.5 mM isopropyl -D-1-thiogalactopyranoside (IPTG). Selected colonies
were screened for the presence of the desired construct by plasmid extraction (QIAprep Spin Miniprep
kit; Qiagen) and restriction digestion with BamHI (Fast Digest BAMHI; Thermo Scientiﬁc). Expression of
smvR from the native promoter was conﬁrmed in the E. coli background by RT-PCR using primers
SMVR-2-F and SMVR-2-R (Table 5). The resulting pGEM-T constructs expressing RS50a smvR (designated
pGEM-T::RS50AsmvR) or empty pGEM-T vector (pGEM-Tempty) were subsequently introduced to P.
mirabilis RS47 by electroporation (0.1-cm gap cuvettes, 1.25 V, 25 F, 200 ). Following electroporation,
cells were recovered in super optimal broth (SOC) medium (20 mM glucose, 10 mM MgCl2, 10 mM
TABLE 5 List of primers used in this study
Target Primer Sequence (5=–3=) Product, application, comments
smvA SMVA-F TCGCCACCCTTATTGCCATT qPCR primer for smvA expression
SMVA-R CGGCGACTAACTGTAAGCGT qPCR primer for smvA expression
smvA SMVA3-F CCTCACTTTTCGGGACAACG Ampliﬁcation of smvA region encompassing target qPCR primers SMVA-F and -R.
Used for construction of qPCR standard
SMVA3-R ACCTAAACGCGCTAGCCAAA Ampliﬁcation of smvA region encompassing target qPCR primers SMVA-F and -R.
Used for construction of qPCR standard
smvR SMVR-BAMHI-F GGATCCCGTTGCAGGCATGCTCATAG Ampliﬁcation of RS50a smvR and upstream promoter region for complementation
of RS47. Primers introduce ﬂanking BamHI restriction sites (underlined bases).
SMVR-BAMHI-R GGATCCCGCCTCTGTGTATTCCGACT Ampliﬁcation of RS50a smvR and upstream promoter region for complementation
of RS47. Primers introduce ﬂanking BamHI restriction sites (underlined bases).
smvR SMVR-2-F GCGCGATTTAATCAGGTGGT Primer for region internal to smvR to conﬁrm expression by RT-PCR.
SMVR-2-R TTCTGGCGTTTGCAGTAACG Primer for region internal to smvR to conﬁrm expression by RT-PCR.
smvR SMVR-FLANK2-F CGTTGCAGGCATGCTCATAG Ampliﬁcation of smvR for BreSeq analysis in isolates B4, RS1, and RS50a.
SMVR-FLANK2-R CGCCTCTGTGTATTCCGACT Ampliﬁcation of smvR for BreSeq analysis in isolates B4, RS1, and RS50a.
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MgSO4, 2.5 mM KCl, 10 mM NaCl, 20 g/liter tryptone, and 5 g/liter yeast extract) for 1 h at 37°C with
shaking, before selection of transformants on nonswarming LB (NSLB) agar supplemented with
100 g/ml ampicillin.
Adaptation of P. mirabilis to chlorhexidine. P. mirabilis isolates RS1, RS50a, and B4 were adapted
to grow at elevated concentrations of CHD as described previously (19). Brieﬂy, 50 l of overnight culture
was used to inoculate 3 ml of TSB supplemented with a starting concentration of 8 g/ml CHD and
incubated at 37°C. After 48 h of incubation, 50 l of the initial culture was transferred to 3 ml of fresh TSB
with double the previous concentration of CHD and incubation continued. This process was repeated for
14 days to a ﬁnal concentration of 512 g/ml CHD. Cells surviving in the ﬁnal culture (512 g/ml CHD)
were passaged 10 times on tryptic soya agar (TSA) in the absence of CHD, and the whole culture was
then stored at –80°C until required.
Analysis of smvR mutations in CHD-adapted mutants using the BreSeq pipeline. Total genomic
DNA from each adapted culture was extracted using the Wizard genomic DNA puriﬁcation kit (Promega).
To amplify smvR, hi-ﬁdelity DreamTaq green PCR master mix (Thermo Scientiﬁc) was used with primers
SMVR-FLANK2-F and SMVR-FLANK2-R (Table 5) (10 pmol/primer) in 50-l reactions with 10- to 20-ng
DNA template. Resulting smvR amplicons were puriﬁed using a QIAquick PCR puriﬁcation kit (Qiagen)
and sequenced by Public Health England Genomic Services and Development Unit (PHE-GSDU) on an
Illumina (HiSeq 2500) instrument, with a minimum of 150 Mb of Q30 quality data obtained for each
culture. The smvR sequences obtained from each CHD-adapted culture were compared with the parental
wild-type sequence using the Breseq pipeline (59). Breseq was run in polymorphism mode with a cutoff
P value of 0.01 to identify and predict the frequency of sequences containing single nucleotide
polymorphisms (SNPs), duplications, and deletions (59).
In vitro models of the catheterized urinary tract. Bladder models representative of the catheter-
ized urinary tract originally described by Stickler et al. (60) were performed with minor modiﬁcations
described by Nzakizwanayo et al. (33). Artiﬁcial urine (AU) was prepared as a concentrated 5 stock
solution containing sodium disulfate (11.5 g/liter), magnesium chloride (hexahydrate) (3.25 g/liter), so-
dium chloride (23 g/liter), trisodium citrate (3.25 g/liter), sodium oxalate (0.1 g/liter), potassium dihydro-
gen orthophosphate (14 g/liter), potassium chloride (8 g/liter), ammonium chloride (5 g/liter), gelatin
(25 g/liter), tryptic soya broth (5 g/liter), calcium chloride dihydrate (3.25 g/liter), and urea (125 g/liter).
Stock solutions of urea and calcium chloride dihydrate were ﬁlter sterilized separately (0.45-m nitro-
cellulose membrane; Sartorius, UK), and other components were sterilized by autoclaving. For in-use
concentrations, all components were combined and diluted to 1 strength using sterile deionized water,
with the ﬁnal pH adjusted to 6.1.
The bladder, consisting of a double-walled glass chamber, was maintained at 37°C by a water jacket
supplied from a circulating water bath. Size 14 all-silicone Foley catheters (Bard, UK) were inserted into
the bladder and the retention balloons inﬂated with 10 ml sterile water. A drainage bag was attached to
the catheter to form a sterile, closed drainage system. AU was supplied to the bladder at a constant rate
of 0.72 ml/min. Models were inoculated with 10 ml of a bacterial culture containing 108 CFU/ml
which were allowed to establish within the bladder for 1 h before AU ﬂow was activated. The number
of viable cells in the bladder residual urine and the pH of the medium were measured at the start and
at blockage.
Data availability. Genome sequences have been deposited in GenBank under the BioProject
accession number PRJNA554808. Proteus mirabilis smvA and smvR sequences can also be found at
GenBank under accession numbers MN265394 and MN265395, respectively.
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